Foundayo vs Mounjaro vs the Wegovy Pill: How Do the GLP-1 Options Compare?

Medically reviewed by Puja Vyas, Senior Clinical Pharmacist.

‍

Foundayo (Orforglipron) just got its MHRA approval on the 10^th of August, 2026, and now women in the UK have four licensed GLP-1 weight loss options: two weekly injections (Wegovy and Mounjaro) and two daily tablets (the Wegovy pill and Orforglipron, brand name Foundayo).

All of them are prescription-only, all work through the same fundamental mechanism, and all have meaningful clinical trial data behind them. The differences are how they work at a chemistry level, how you take them, and what the average weight loss figures look like across different trials.

‍

Key Takeaways

• There are now two MHRA-licensed oral GLP-1 weight loss tablets in the UK: the Wegovy pill (oral semaglutide) and orforglipron (Foundayo), approved 10 August 2026
• The Wegovy pill requires a morning fasting routine. Orforglipron has no food or water restrictions and can be taken at any time
• In the ACHIEVE-3 head-to-head trial (The Lancet, February 2026), orforglipron produced 73.6% greater relative weight loss than oral semaglutide in people with type 2 diabetes: 9.2% vs 5.3%
• Across non-diabetes populations: Wegovy pill 13.6% at 64 weeks (OASIS 4), orforglipron 12.4% at 72 weeks (ATTAIN-1)
• Mounjaro (tirzepatide injection) remains the highest-performing option at 22.5% average weight loss at 72 weeks (SURMOUNT-1)
• Orforglipron is not yet available on levothyroxine compatibility data, making it potentially useful for women with thyroid conditions who struggle with the Wegovy pill's fasting window

Let’s start with a top-level comparison -

GLP-1 Tablets vs GLP-1 Injections: What's the Difference?

GLP-1 tablets and injections both work by mimicking GLP-1, a hormone in your gut that tells your brain you are full, slows how quickly food leaves your stomach, and regulates blood sugar. The difference is not the destination but the path.

What Makes a GLP-1 Medicine a Tablet Rather Than an Injection

Initially, GLP-1 medications were only available as injections. This is because they were made up of peptide molecules that if swallowed, get broken down by stomach acid, leaving no impact. So, for them to enter your bloodstream from a tablet would require either a bypass mechanism or building a molecule that doesn't have the problem in the first place.

The Wegovy pill uses the first option, a compound called SNAC, that creates a temporary window in the stomach that allows semaglutide to pass through the stomach lining. This is why it must be taken on an empty stomach with a precise amount of water, followed by a 30-minute fast. The absorption window is narrow, precise, and food-sensitive.

The makers of Orforglipron (Foundayo), Eli Lilly, went for the other option. They built a small non-peptide molecule, that survives stomach acid on its own without any special carrier. It absorbs reliably whether you have eaten or not, at any time of day, with any amount of water.

Here’s some detailed guides we’ve written about Orforglipron if you’re more interested - What is orforglipron (Foundayo)? → & Foundayo: Availability, price & NHS access →

‍

Now let’s compare apples to apples – pill to pill -

Foundayo (Orforglipron) vs the Wegovy Pill

This section is important for women who want a needle-free option. Both are once-daily oral GLP-1 medicines. Both are now MHRA-licensed. The differences are real and worth understanding.

The Fasting Routine: Orforglipron's Biggest Practical Advantage

The Wegovy pill comes with a set of strict instructions about how it’s supposed to be taken. An empty stomach, first thing in the morning, with no more than 120ml of plain still water, followed by a 30-minute wait before you eat, drink anything else, including any other oral medications.

Orforglipron doesn’t come with any particular restrictions. You take it once a day, at whatever time suits you, with any amount of water and any food. You could take it with your morning coffee, at lunch, or before bed.

If you found the Wegovy pill's routine difficult to maintain consistently, this is a genuine practical advantage. And in the end, consistency is what determines your results, not trial averages.  

The thing nobody tells you about the Wegovy pill: it works brilliantly when you do the routine right, but the 30-minute fasting window is the one thing that trips women up most often. School runs, early meetings, toddlers who need breakfast immediately, not having the stomach for a tablet first thing when nauseous.

Orforglipron simply removes that friction entirely. Take it whenever. That’s not a small thing when you’re doing this every day for a year.

Weight Loss Results Compared: What the Data Shows

In non-diabetes populations: the Wegovy pill produced 13.6% average weight loss at 64 weeks in the OASIS 4 trial. Orforglipron produced 12.4% average weight loss at 72 weeks in ATTAIN-1. An important thing to note here is that while the results are similar, they are from different trials with different populations and durations, so a direct comparison should be done carefully.

In type 2 diabetes populations (where we’ve got a direct head-to-head comparison): ACHIEVE-3 (published in The Lancet, February 2026) was the first Phase 3 trial directly comparing Orforglipron and oral semaglutide. At the highest doses, Orforglipron (36mg) produced 9.2% body weight reduction versus 5.3% with oral semaglutide (14mg). A 73.6% higher relative weight loss. HbA1c reduction was also greater: 2.2% with Orforglipron vs 1.4% with oral semaglutide.

Before you reach conclusions, here’s an important note: the ACHIEVE-3 trial compared oral semaglutide’s standard-dose (up to 14mg, the diabetes-licensed dose), not the higher-dose Wegovy pill formulation used for weight management (25mg). Hence, even this head-to-head comparison may not be conclusive.

Orforglipron Will Suit your Better Over the Wegovy Pill If -

• You’re on levothyroxine: thyroid medication typically requires 30 to 60 minutes before food, already making mornings complicated. Adding the Wegovy pill's fasting window on top can get logistically difficult to maintain. Orforglipron sidesteps this entirely.
• Women with PCOS or insulin resistance: both medications improve insulin sensitivity, but orforglipron's simpler routine can mean better adherence, which, in the end, determines the outcome.
• Women who repeatedly miss or take the Wegovy pill incorrectly: Irrespective of the medicine, consistency is the key to effectiveness. If the fasting routine is the thing standing between you and consistent dosing, Orforglipron is a genuinely better fit.

Still feel Wegovy Pill is the right choice for you? It can be. Get to know more about Wegovy pill at SheMed →

Foundayo (Orforglipron) vs Mounjaro (Tirzepatide)

This comparison between an oral tablet and a weekly injection is not just about weight loss numbers but about what trade-offs you are willing to make.

Weight Loss Results: The Efficacy Gap

Mounjaro currently produces the highest average weight loss of any licensed weight management medicine in the UK with an average body weight reduction of 22.5% at 72 weeks at the 15mg dose.

In a head-to-head comparison with the Wegovy injection, Mounjaro produced 20.2% average weight loss vs Wegovy’s 13.7% at 72 weeks. This confirmed that the advantage persists head-to-head.

Orforglipron (Foundayo), on the other hand, produced a 12.4% average weight loss with a 36mg dose at 72 weeks. Substantially below Mounjaro on average results.

So, if maximum average weight loss is your primary goal and you are able to self-inject weekly, Mounjaro remains the most effective option available for you.

Curious to know more about the difference between Mounjaro and Wegovy injections? Here’s an article we’ve written dedicated to it - Mounjaro vs Wegovy

Why Injections Currently Outperform Oral Options

Pharmacokinetics. When you inject a GLP-1 medicine subcutaneously (just under your skin), it enters your bloodstream with almost full bioavailability. With any oral GLP-1, even with optimised delivery technology, some of the drug is processed before it reaches your blood circulation system. Orforglipron's non-peptide design is the best oral delivery yet developed, but it cannot beat the absorption percentage of an injection.

This doesn’t automatically mean that you should go for injections. If 12 to 13% weight loss, without any injections, fits your goals and suits your lifestyle better, the additional results from a weekly injection may not be worth it. The right medicine is the one you can take consistently,

Moreover, not every medicine suits everyone. Your metabolic profile, existing medical conditions (if any), etc. are important factors to consider before choosing the right medicine.

This is where a full-at-home blood test by SheMed before anything is prescribed comes into the picture. We’ll tell you more about it below.

Orforglipron may be better for you over Mounjaro if -

• You’ve got significant needle anxiety and are not willing to self-inject
• You’ve tried the Wegovy pill but found the morning routine unsustainable
• You want the simplest possible daily routine alongside lifestyle changes
• You manage type 2 diabetes alongside weight where orforglipron's glycaemic advantage (2.2% HbA1c reduction vs 1.4% for oral semaglutide in ACHIEVE-3) is clinically meaningful

Whatever you feel is right for you, we’ve got them all (Orforglipron soon): SheMed treatment plans →

Side-by-Side Comparison: Orforglipron vs Wegovy Pill vs Mounjaro

Source: MHRA GOV.UK approval announcements, NEJM trial publications, NICE guidance April 2026.

Which GLP-1 Option Might Suit You?

The right answer depends on your health picture, your goals, your lifestyle, and your tolerance for the trade-offs each option brings. Here are some points that can help you know how to think about it -

• If you want maximum average weight loss and can inject weekly: Mounjaro currently has the strongest efficacy data.
• If you want a daily tablet with no restrictions and type 2 diabetes or PCOS: Orforglipron offers the simplest routine and the best head-to-head data against oral semaglutide.
• If you want a daily tablet with established longer safety data: the Wegovy pill has been available longer and has more real-world experience in the UK at this point.
• If cardiovascular risk reduction matters alongside weight loss: the Wegovy injection is the only currently licensed option in the UK with an MHRA-approved cardiovascular benefit (NICE, April 2026). This is a unique advantage for women with relevant cardiac history.

While we’ve tried to give you all important information you need to know about the four currently available options, your decision should be made after consulting a clinician and not just this article.

The blood test SheMed includes with every plan gives our clinical team the thyroid, HbA1c, cholesterol, and metabolic information needed to advise you on which option makes most sense for your specific picture.

🌸  All three options. One clinical team. SheMed offers the Wegovy pill, Mounjaro and Wegovy injections, and will be adding Orforglipron shortly. Free at-home blood test included, clinician-led prescribing, side-effect support.

 Only from £59 for your first month. Start your consultation →

‍

Feel like knowing more about Foundayo? Keep reading!

Orforglipron (Foundayo) in the UK: Availability, Price and NHS Access →

What Is Orforglipron (Foundayo)? The New Oral GLP-1 Weight Loss Pill Explained →

‍

Frequently Asked Questions

Is Foundayo (Orforglipron) as effective as Mounjaro?

Not as per the average weight loss based on current trial data. Mounjaro (tirzepatide injection) produces 22.5% average weight loss at 72 weeks (SURMOUNT-1, 15mg), substantially higher than orforglipron's 12.4% at 72 weeks (ATTAIN-1, 36mg).

What's the difference between Foundayo and the Wegovy pill?

Both are once-daily oral GLP-1 medicines, but their chemistry and dosing rules differ. The Wegovy pill requires a strict morning fasting protocol: empty stomach, 120ml plain still water, 30-minute wait. Orforglipron molecule that can be taken at any time with any food or water. In non-diabetes weight loss trials, results are broadly similar (13.6% vs 12.4%). In the ACHIEVE-3 diabetes head-to-head, Orforglipron outperformed oral semaglutide significantly.

Can you take Foundayo with food?

Yes. Orforglipron (Foundayo) can be taken at any time of day, with or without food, and with any amount of water. There are no food or water restrictions.

Which GLP-1 pill is available in the UK right now?

Both the Wegovy pill (oral semaglutide, approved June 2026) and Orforglipron (Foundayo, approved by the MHRA on 10 August 2026) are now licensed in the UK. Both require a private prescription at this stage, as NHS access for both is pending NICE technology appraisals. SheMed currently prescribes the Wegovy pill and will add Orforglipron to its programme shortly.

Does Orforglipron interact with levothyroxine?

No specific interaction between Orforglipron and levothyroxine has been identified. Because Orforglipron has no fasting requirement and can be taken at any time, it avoids the practical complication of the Wegovy pill's fasting window, which can conflict with levothyroxine's own timing requirements. Women on levothyroxine should mention this to their prescribing clinician when discussing options.

‍

Sources and Further Reading

1. MHRA GOV.UK – UK First in Europe to Authorise Orforglipron (10 August 2026)

2. NEJM – ATTAIN-1: Orforglipron for Obesity (Wharton S et al., 2025)

3. Eli Lilly Press Release – ACHIEVE-3: Orforglipron Superior to Oral Semaglutide (26 February 2026)

4. NEJM – OASIS 4: Oral Semaglutide for Obesity (2023)

5. Jastreboff AM et al. – SURMOUNT-1: Tirzepatide for Obesity. NEJM. 2022;387(3):205–216

6. NICE – Semaglutide for Cardiovascular Risk Reduction (April 2026)

7. FDA Prescribing Information – Foundayo (Orforglipron)

8. The Pharmaceutical Journal – MHRA Approves Orforglipron (10 August 2026)

‍